The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: A propensity score analysis
Open Access
- 24 June 2008
- journal article
- pediatric rheumatology
- Published by Wiley in Arthritis Care & Research
- Vol. 59 (7), 989-995
- https://doi.org/10.1002/art.23829
Abstract
Objective To compare outcomes at 36 months in patients newly diagnosed with juvenile dermatomyositis (DM) treated with aggressive versus standard therapy. Methods At diagnosis, 139 untreated juvenile DM patients were given aggressive therapy (intravenous methylprednisolone or oral prednisone 5–30 mg/kg/day; n = 76) or standard therapy (1–2 mg/kg/day; n = 63) by the treating physician. Aggressive therapy patients were more ill at diagnosis. Matching was based on the propensity for aggressive therapy because propensity scoring can reduce confounding by indication. Logistic regression of the matched data determined predictors of outcomes, controlling for clinical confounders and propensity score. Outcomes comprised Disease Activity Score (DAS) for skin and muscle, range of motion (ROM), and calcification. Results Sex, race, and age were similar between groups, and initial DAS weakness and ROM significantly predicted the therapy chosen. Based on propensity scores, 42 patients from each group were well matched. In the matched pairs, there were no significant differences in outcomes. Methotrexate use (odds ratio [OR] 3.6, 95% confidence interval [95% CI] 1.15–11.5) and duration of untreated disease (OR 1.2, 95% CI 1–1.38) were associated with ROM loss, hydroxychloroquine use (OR 11.2, 95% CI 3.7–33) and calcification (OR 6.8, 95% CI 1.8–25.4) with persistent rash, abnormal baseline lactate dehydrogenase (OR 11.2, 95% CI 1.4–92) and age at onset (OR 1.3, 95% CI 1–1.4) with weakness, and duration of untreated disease (OR 1.2, 95% CI 1–1.39) with calcification. Conclusion Using a retrospective, nonrandomized design with propensity score matching, there was little difference in efficacy outcomes between aggressive and standard therapy; however, the sickest patients were treated with aggressive therapy and were not included in the matched analysis. Comprehensive clinical studies are needed to determine therapeutic pathways to the best outcome.Keywords
This publication has 49 references indexed in Scilit:
- Microsporidia and Acanthamoeba: the role of emerging corneal pathogensEye, 2011
- National Outbreak ofAcanthamoebaKeratitis Associated with Use of a Contact Lens Solution, United StatesEmerging Infectious Diseases, 2009
- Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositisArthritis Care & Research, 2008
- Persistent association of nailfold capillaroscopy changes and skin involvement over thirty‐six months with duration of untreated disease in patients with juvenile dermatomyositisArthritis & Rheumatism, 2008
- Gender Differences in Health Care Utilization Among Veterans with Chronic PainJournal of General Internal Medicine, 2007
- Composition of calcifications in children with juvenile dermatomyositis: Association with chronic cutaneous inflammationArthritis & Rheumatism, 2006
- Duration of illness is an important variable for untreated children with juvenile dermatomyositisThe Journal of Pediatrics, 2006
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002
- Childhood dermatomyositis: Factors predicting functional outcome and development of dystrophic calcificationThe Journal of Pediatrics, 1983
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983